A review of six placebo-managed clinical trials with 1,134 whole individuals concluded that cannabinoids (nabiximols, dronabinol, and THC/CBD) have been affiliated with a greater average enhancement about the Ashworth scale for spasticity in multiple sclerosis people in comparison with placebo,